NCT03167788 is a Phase 2 clinical trial of rejuvesol Solution in Organ Failure, Multiple, sponsored by University of Leicester.

Who is sponsoring NCT03167788?

NCT03167788 is sponsored by University of Leicester.

What drugs are being tested in NCT03167788?

Interventions in NCT03167788: rejuvesol Solution, Standard Care.

What condition does NCT03167788 study?

NCT03167788 studies Organ Failure, Multiple, Inflammation, Sepsis.

Is NCT03167788 still recruiting?

NCT03167788 is currently withdrawn. Last updated 27 April 2021.

Last reviewed 2021-04-27 · How we verify

NCT03167788

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A RANDOMISED CONTROLLED TRIAL OF RED CELL REJUVENATION FOR THE ATTENUATION OF TRANSFUSION ASSOCIATED ORGAN INJURY IN CARDIAC SURGERY: The REDJUVENATE Trial

Withdrawn Phase 2 Last updated 27 April 2021

What this trial tests

Phase 2 trial testing rejuvesol Solution in Organ Failure, Multiple. Withdrawn.

Timeline

1 December 2020

Primary endpoint
1 December 2020

1 December 2020

Quick facts

Lead sponsor	University of Leicester
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Start date	1 December 2020
Primary completion	1 December 2020
Estimated completion	1 December 2020
Sites	1 location across United Kingdom

Drugs / interventions tested

rejuvesol Solution
Standard Care — full drug profile →

Conditions studied

Organ Failure, Multiple — all drugs for Organ Failure, Multiple →
Inflammation — all drugs for Inflammation →
Sepsis — all drugs for Sepsis →

Sponsor

University of Leicester

Who can join

18 and older, any sex, with Organ Failure, Multiple or Inflammation. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Renal injury
Time frame: baseline to 96 hours postoperatively
measurement of serum creatinine
Myocardial injury
Time frame: baseline to 72 hours postoperatively
measurement of serum troponin

Sponsor's own description

The REDJUVENATE Trial proposes to test the hypothesis that postoperative organ injury and inflammation will be less if patients undergoing cardiac surgery who are at risk of large volume blood transfusion (defined as the administration of ≥4 units of red cells) receive rejuvenated washed cells compared to standard care (unwashed aged stored cells).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Rejuvenation of allogenic red cells: benefits and risks.
Aujla H, Woźniak M, Kumar T, Murphy GJ, et al · · 2018 · cited 11× · PMID 29864792 · DOI 10.1111/vox.12666
Red blood cell transfusion management for people undergoing cardiac surgery for congenital heart disease.
Wilkinson KL, Kimber C, Allana A, Dorée C, et al · · 2025 · cited 1× · PMID 40105353 · DOI 10.1002/14651858.cd009752.pub3

Verify or expand the search:

Other recruiting trials for Organ Failure, Multiple

Currently open trials in the same condition.

NCT03547232 — Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial) · Phase 4 · recruiting
NCT06330610 — Evaluation of the Efficiency of Intermittent Enteral Nutrition on Multi-organ Failure From Patients With Mechanical Vent · NA · recruiting
NCT06452966 — The Impact and Effect of Traditional Chinese Medicine Treatment on Organ Failure in Critically Ill Patients · NA · recruiting
NCT05872152 — Impact of Fourier Transform Infrared Spectroscopy (FTIRS) in ICUs · NA · recruiting
NCT04695119 — Sepsis in the ICU-II · active not recruiting

Other University of Leicester trials

Trials by the same sponsor.

NCT07389785 — Age Related Chromatin Remodelling as a Therapeutic Target for Organ Protection in Cardiac Surgery · active not recruiting
NCT07014579 — Using Heart Electrical Signals to Study How Well Treatments Prevent Dangerous Heart Rhythms in Active People · not yet recruiting
NCT06955663 — Exercise Support and Rehabilitation for Patients After Spontaneous Coronary Artery Dissection · NA · recruiting
NCT06629675 — Make Every Step Count: Personalised Music Feedback to Walking for People Living With COPD · NA · recruiting
NCT06844656 — Understanding the Increased Risk of Atrial Fibrillation in Athletes: a Case-control Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03167788 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Leicester
Last refreshed: 27 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03167788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing